Summary & Overview
HCPCS S0179: Megestrol Acetate, Oral, 20 mg
HCPCS Level II code S0179 identifies megestrol acetate, oral, 20 mg, a formulation commonly used for appetite stimulation and management of cachexia. Nationally, this code matters for pharmacy billing, outpatient medication coverage determinations, and utilization tracking where megestrol acetate is prescribed. It affects payer drug policies, medical necessity reviews, and pharmacy benefit management across public and commercial plans.
Key payers covered in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of where this code applies clinically and operationally, how major payers approach coverage and reimbursement at a high level, and the common billing context for outpatient pharmacy and clinic-dispensed oral therapies. The publication provides benchmarks and policy context relevant to payer coverage decisions, prior authorization practices, and coding accuracy for service lines that dispense oral oncologic or appetite-stimulant medications.
The report also outlines clinical context for megestrol acetate use, typical sites of service for billing, and identifies data gaps where input was not provided. Data not available in the input.
Billing Code Overview
HCPCS Level II code S0179 represents megestrol acetate, oral, 20 mg. This billing code denotes a prescription oral pharmacologic therapy typically used for appetite stimulation and weight loss management in patients with cachexia or anorexia associated with chronic illness, or for other clinically indicated uses of megestrol acetate.
Service Type: Oral medication administration (pharmacy-dispensed)
Typical Site of Service: Outpatient pharmacy, clinic-based dispensing, or outpatient prescription use
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient receiving S0179 (megestrol acetate, oral, 20 mg) is an adult oncology or palliative care patient with cancer-associated anorexia, cachexia, or significant unintentional weight loss. The clinical workflow begins with an outpatient oncology or palliative medicine visit where weight loss, decreased appetite, and functional decline are documented. The treating clinician (medical oncologist, palliative care physician, or hospice physician) assesses the patient for reversible causes of anorexia, reviews current medications, and discusses goals of care. After informed discussion about benefits and risks, the prescriber writes an order for oral megestrol acetate and documents indication, dose, duration, and monitoring plan. The medication is dispensed by an outpatient pharmacy or provided by hospice/home health services for home administration. Follow-up visits evaluate appetite, weight, fluid retention, venous thromboembolism risk, and adverse effects; adjustments or discontinuation are documented in the medical record. Billing uses S0179 for the drug, with applicable modifiers for payer reporting and services such as hospice (AS), skilled nursing (62), or facility-specific modifiers as required by the payer policy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|